Database Query Results : , , IGFBP3

IGFBP3, Insulin-Like Growth Factor Binding Protein-3: Click to Expand ⟱
Source:
Type:
One of the six members of the IGFBP family, is a key protein in the IGF pathway. IGFBP-3 is the most abundant in the blood circulation. Prostate specific antigen (PSA), which is frequently used as a clinical tumor marker for prostate cancer, cleaves IGFBP-3.

Tumor Types:
IGFBP-3 expression can vary significantly across different cancer types. It is often downregulated in several malignancies, including breast cancer, prostate cancer, colorectal cancer, and lung cancer.
In some cases, low levels of IGFBP-3 are associated with tumor progression and poor clinical outcomes.

Tumor Suppressor Functions:
IGFBP-3 is often considered a tumor suppressor due to its ability to inhibit the actions of IGF-1 and IGF-2, which promote cell proliferation and survival. By binding to IGFs, IGFBP-3 can prevent their interaction with IGF receptors, thereby inhibiting their mitogenic effects.

High levels of IGFBP-3 are generally associated with a favorable prognosis in several cancers. For example, elevated IGFBP-3 levels in breast cancer and prostate cancer have been linked to better survival outcomes.
Conversely, low levels of IGFBP-3 are often associated with aggressive tumor behavior and poorer prognosis.
Scientific Papers found: Click to Expand⟱
2640- Api,    Apigenin: A Promising Molecule for Cancer Prevention
- Review, Var, NA
chemoPv↑, ITGB4↓, TumCI↓, TumMeta↓, Akt↓, ERK↓, p‑JNK↓, *Inflam↓, *PKCδ↓, *MAPK↓, EGFR↓, CK2↓, TumCCA↑, CDK1↓, P53↓, P21↑, Bax:Bcl2↑, Cyt‑c↑, APAF1↑, Casp↑, cl‑PARP↑, VEGF↓, Hif1a↓, IGF-1↓, IGFBP3↑, E-cadherin↑, β-catenin/ZEB1↓, HSPs↓, Telomerase↓, FASN↓, MMPs↓, HER2/EBBR2↓, CK2↓, eff↑, AntiAg↑, eff↑, FAK↓, ROS↑, Bcl-2↓, Cyt‑c↑, cl‑Casp3↑, cl‑Casp7↑, cl‑Casp8↑, cl‑Casp9↑, cl‑IAP2↑, AR↓, PSA↓, p‑pRB↓, p‑GSK‐3β↓, CDK4↓, ChemoSen↑, Ca+2↑, cal2↑,
2711- BBR,    Berberine inhibits the progression of breast cancer by regulating METTL3-mediated m6A modification of FGF7 mRNA
- in-vitro, BC, MCF-7 - in-vitro, BC, MDA-MB-231 - in-vivo, NA, NA
TumCP↓, TumCI↓, TumCMig↓, Apoptosis↑, FGF↓, IGFBP3↑,
1842- dietFMD,    Safety and Feasibility of Fasting-Mimicking Diet and Effects on Nutritional Status and Circulating Metabolic and Inflammatory Factors in Cancer Patients Undergoing Active Treatment
- Trial, Var, NA
Strength∅, Weight∅, IGF-1↓, IGFBP3↑, IGFBP1↑, eff↑,
2028- PB,    Potential of Phenylbutyrate as Adjuvant Chemotherapy: An Overview of Cellular and Molecular Anticancer Mechanisms
- Review, Var, NA
HDAC↓, TumCCA↑, P21↑, Dose↝, Telomerase↓, IGFBP3↑, p‑p38↑, JNK↑, ERK↑, BAX↑, Casp3↑, Bcl-2↓, Cyt‑c↝, FAK↓, survivin↓, VEGF↓, angioG↓, DNArepair↓, TumMeta↓, HSP27↑, ASK1↑, ROS↑, eff↑, ER Stress↓, GRP78/BiP↓, CHOP↑, AR↓, other?,
3369- QC,    Pharmacological basis and new insights of quercetin action in respect to its anti-cancer effects
- Review, Pca, NA
FAK↓, TumCCA↑, p‑pRB↓, CDK2↑, CycB/CCNB1↓, CDK1↓, EMT↓, PI3K↓, MAPK↓, Wnt↓, ROS↑, miR-21↑, Akt↓, NF-kB↓, FasL↑, Bak↑, BAX↑, Bcl-2↓, Casp3↓, Casp9↑, P53↑, p38↑, MAPK↑, Cyt‑c↑, PARP↓, CHOP↑, ROS↓, LDH↑, GRP78/BiP↑, ERK↑, MDA↓, SOD↑, GSH↑, NRF2↑, VEGF↓, PDGF↓, EGF↓, FGF↓, TNF-α↓, TGF-β↓, VEGFR2↓, EGFR↓, FGFR1↓, mTOR↓, cMyc↓, MMPs↓, LC3B-II↑, Beclin-1↑, IL1β↓, CRP↓, IL10↓, COX2↓, IL6↓, TLR4↓, Shh↓, HER2/EBBR2↓, NOTCH↓, DR5↑, HSP70/HSPA5↓, CSCs↓, angioG↓, MMP2↓, MMP9↓, IGFBP3↑, uPA↓, uPAR↓, RAS↓, Raf↓, TSP-1↑,
78- QC,    Effects of quercetin on insulin-like growth factors (IGFs) and their binding protein-3 (IGFBP-3) secretion and induction of apoptosis in human prostate cancer cells
- in-vitro, Pca, PC3
IGF-1↓, IGF-2↓, IGFBP3↑, Bcl-2↓, Bcl-xL↓, Casp3↑,
83- QC,    Quercetin induces p53-independent apoptosis in human prostate cancer cells by modulating Bcl-2-related proteins: a possible mediation by IGFBP-3
- in-vitro, Pca, PC3
Bcl-2↓, Bcl-xL↓, BAX↑, IGFBP3↑,
86- QC,    Quercetin regulates insulin like growth factor signaling and induces intrinsic and extrinsic pathway mediated apoptosis in androgen independent prostate cancer cells (PC-3)
- in-vitro, Pca, PC3
BAD↑, IGFBP3↑, Cyt‑c↑, cl‑Casp9↑, Casp10↑, cl‑PARP↑, Casp3↑, IGF-1R↓, PI3K↓, p‑Akt↓, cycD1/CCND1↓, IGF-1↓, IGF-2↓, IGF-1R↓,
3055- RES,    Resveratrol and Tumor Microenvironment: Mechanistic Basis and Therapeutic Targets
- Review, Var, NA
BioAv↓, BioAv↓, Dose↑, eff↑, eff↑, Dose↑, BioAv↑, ROS↑, MMP↓, P21↑, p27↑, TumCCA↑, ChemoSen↑, COX2↓, 5LO↓, VEGF↓, IL1↓, IL6↓, IL8↓, AR↓, PSA↓, MAPK↓, Hif1a↓, Glycolysis↓, miR-21↓, PTEN↑, Half-Life↝, *IGF-1↓, *IGFBP3↑, Half-Life↓,
3010- RosA,    Exploring the mechanism of rosmarinic acid in the treatment of lung adenocarcinoma based on bioinformatics methods and experimental validation
- in-vitro, Lung, A549 - in-vivo, NA, NA
TumCG↓, Ki-67↓, FABP4↑, PPARα↑, ROS↑, Apoptosis↑, MMP9↓, IGFBP3↓, MMP2↓, EMT↓, TumCI↓, PI3K↓, Akt↓, mTOR↓, Gli1↓, PPARγ↑, Cyt‑c↑,
3282- SIL,    Role of Silymarin in Cancer Treatment: Facts, Hypotheses, and Questions
- Review, NA, NA
hepatoP↑, AntiCan↑, TumCMig↓, Hif1a↓, selectivity↑, toxicity∅, *antiOx↑, *Inflam↓, TumCCA↑, P21↑, CDK4↓, NF-kB↓, ERK↓, PSA↓, TumCG↓, p27↑, COX2↓, IL1↓, VEGF↓, IGFBP3↑, AR↓, STAT3↓, Telomerase↓, Cyt‑c↑, Casp↑, eff↝, HDAC↓, HATs↑, Zeb1↓, E-cadherin↑, miR-203↑, NHE1↓, MMP2↓, MMP9↓, PGE2↓, Vim↓, Wnt↓, angioG↓, VEGF↓, *TIMP1↓, EMT↓, TGF-β↓, CD44↓, EGFR↓, PDGF↓, *IL8↓, SREBP1↓, MMP↓, ATP↓, uPA↓, PD-L1↓, NOTCH↓, *SIRT1↑, SIRT1↓, CA↓, Ca+2↑, chemoP↑, cardioP↑, Dose↝, Half-Life↝, BioAv↓, BioAv↓, BioAv↓, toxicity↝, Half-Life↓, ROS↓, FAK↓,

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 11

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned ⓘ

chemoPv↑, 1,  

Redox & Oxidative Stress ⓘ

GSH↑, 1,   MDA↓, 1,   NRF2↑, 1,   ROS↓, 2,   ROS↑, 5,   SOD↑, 1,  

Mitochondria & Bioenergetics ⓘ

ATP↓, 1,   EGF↓, 1,   FGFR1↓, 1,   MMP↓, 2,   Raf↓, 1,  

Core Metabolism/Glycolysis ⓘ

cMyc↓, 1,   FABP4↑, 1,   FASN↓, 1,   Glycolysis↓, 1,   LDH↑, 1,   PPARα↑, 1,   PPARγ↑, 1,   SIRT1↓, 1,   SREBP1↓, 1,  

Cell Death ⓘ

Akt↓, 3,   p‑Akt↓, 1,   APAF1↑, 1,   Apoptosis↑, 2,   ASK1↑, 1,   BAD↑, 1,   Bak↑, 1,   BAX↑, 3,   Bax:Bcl2↑, 1,   Bcl-2↓, 5,   Bcl-xL↓, 2,   Casp↑, 2,   Casp10↑, 1,   Casp3↓, 1,   Casp3↑, 3,   cl‑Casp3↑, 1,   cl‑Casp7↑, 1,   cl‑Casp8↑, 1,   Casp9↑, 1,   cl‑Casp9↑, 2,   CK2↓, 2,   Cyt‑c↑, 6,   Cyt‑c↝, 1,   DR5↑, 1,   FasL↑, 1,   cl‑IAP2↑, 1,   JNK↑, 1,   p‑JNK↓, 1,   MAPK↓, 2,   MAPK↑, 1,   p27↑, 2,   p38↑, 1,   p‑p38↑, 1,   survivin↓, 1,   Telomerase↓, 3,  

Kinase & Signal Transduction ⓘ

HER2/EBBR2↓, 2,  

Transcription & Epigenetics ⓘ

HATs↑, 1,   miR-21↓, 1,   miR-21↑, 1,   other?, 1,   p‑pRB↓, 2,  

Protein Folding & ER Stress ⓘ

CHOP↑, 2,   ER Stress↓, 1,   GRP78/BiP↓, 1,   GRP78/BiP↑, 1,   HSP27↑, 1,   HSP70/HSPA5↓, 1,   HSPs↓, 1,  

Autophagy & Lysosomes ⓘ

Beclin-1↑, 1,   LC3B-II↑, 1,  

DNA Damage & Repair ⓘ

DNArepair↓, 1,   P53↓, 1,   P53↑, 1,   PARP↓, 1,   cl‑PARP↑, 2,  

Cell Cycle & Senescence ⓘ

CDK1↓, 2,   CDK2↑, 1,   CDK4↓, 2,   CycB/CCNB1↓, 1,   cycD1/CCND1↓, 1,   P21↑, 4,   TumCCA↑, 5,  

Proliferation, Differentiation & Cell State ⓘ

CD44↓, 1,   CSCs↓, 1,   EMT↓, 3,   ERK↓, 2,   ERK↑, 2,   FGF↓, 2,   Gli1↓, 1,   p‑GSK‐3β↓, 1,   HDAC↓, 2,   IGF-1↓, 4,   IGF-1R↓, 2,   IGF-2↓, 2,   IGFBP1↑, 1,   IGFBP3↓, 1,   IGFBP3↑, 9,   mTOR↓, 2,   NOTCH↓, 2,   PI3K↓, 3,   PTEN↑, 1,   RAS↓, 1,   Shh↓, 1,   STAT3↓, 1,   TumCG↓, 2,   Wnt↓, 2,  

Migration ⓘ

5LO↓, 1,   AntiAg↑, 1,   CA↓, 1,   Ca+2↑, 2,   cal2↑, 1,   E-cadherin↑, 2,   FAK↓, 4,   ITGB4↓, 1,   Ki-67↓, 1,   miR-203↑, 1,   MMP2↓, 3,   MMP9↓, 3,   MMPs↓, 2,   PDGF↓, 2,   TGF-β↓, 2,   TSP-1↑, 1,   TumCI↓, 3,   TumCMig↓, 2,   TumCP↓, 1,   TumMeta↓, 2,   uPA↓, 2,   uPAR↓, 1,   Vim↓, 1,   Zeb1↓, 1,   β-catenin/ZEB1↓, 1,  

Angiogenesis & Vasculature ⓘ

angioG↓, 3,   EGFR↓, 3,   Hif1a↓, 3,   VEGF↓, 6,   VEGFR2↓, 1,  

Barriers & Transport ⓘ

NHE1↓, 1,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 3,   CRP↓, 1,   IL1↓, 2,   IL10↓, 1,   IL1β↓, 1,   IL6↓, 2,   IL8↓, 1,   NF-kB↓, 2,   PD-L1↓, 1,   PGE2↓, 1,   PSA↓, 3,   TLR4↓, 1,   TNF-α↓, 1,  

Hormonal & Nuclear Receptors ⓘ

AR↓, 4,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 5,   BioAv↑, 1,   ChemoSen↑, 2,   Dose↑, 2,   Dose↝, 2,   eff↑, 6,   eff↝, 1,   Half-Life↓, 2,   Half-Life↝, 2,   selectivity↑, 1,  

Clinical Biomarkers ⓘ

AR↓, 4,   CRP↓, 1,   EGFR↓, 3,   HER2/EBBR2↓, 2,   IL6↓, 2,   Ki-67↓, 1,   LDH↑, 1,   PD-L1↓, 1,   PSA↓, 3,  

Functional Outcomes ⓘ

AntiCan↑, 1,   cardioP↑, 1,   chemoP↑, 1,   hepatoP↑, 1,   Strength∅, 1,   toxicity↝, 1,   toxicity∅, 1,   Weight∅, 1,  
Total Targets: 179

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 1,  

Core Metabolism/Glycolysis ⓘ

SIRT1↑, 1,  

Cell Death ⓘ

MAPK↓, 1,  

Proliferation, Differentiation & Cell State ⓘ

IGF-1↓, 1,   IGFBP3↑, 1,  

Migration ⓘ

PKCδ↓, 1,   TIMP1↓, 1,  

Immune & Inflammatory Signaling ⓘ

IL8↓, 1,   Inflam↓, 2,  
Total Targets: 9

Scientific Paper Hit Count for: IGFBP3, Insulin-Like Growth Factor Binding Protein-3
4 Quercetin
1 Apigenin (mainly Parsley)
1 Berberine
1 diet FMD Fasting Mimicking Diet
1 Phenylbutyrate
1 Resveratrol
1 Rosmarinic acid
1 Silymarin (Milk Thistle) silibinin
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:417  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page